Comerica Bank
CDTX

Comerica Bank’s Cidara Therapeutics CDTX Stock Holding History

Comerica Bank’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.56K Sell
12
-8
-40% -$1.29K ﹤0.01% 3500
2025
Q3 		$1.92K Buy
+20
New +$1.28K ﹤0.01% 3535

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Comerica Bank's CDTX Position: Q4 2025 in Review

Comerica Bank reduced its Cidara Therapeutics (CDTX) stake by 40% in Q4 2025, selling an estimated $1.29K and leaving 12 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3500.

Comerica Bank first reported a position in CDTX in Q3 2025 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Comerica Bank held 12 shares of Cidara Therapeutics worth $2.56K as of Q4 2025.
  • Comerica Bank sold 8 Cidara Therapeutics shares in Q4 2025, an estimated $1.29K.
  • Cidara Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3500 holding.
  • Comerica Bank first reported a position in Cidara Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.